scholarly journals Functional bowel disorders and functional abdominal pain

Gut ◽  
1999 ◽  
Vol 45 (Supplement 2) ◽  
pp. ii43-ii47 ◽  
Author(s):  
W G Thompson ◽  
G F Longstreth ◽  
D A Drossman ◽  
K W Heaton ◽  
E J Irvine ◽  
...  
2000 ◽  
Vol 278 (5) ◽  
pp. G670-G676 ◽  
Author(s):  
Lionel Buéno ◽  
Jean Fioramonti ◽  
Rafael Garcia-Villar

Visceral pain is the major cause of consulting in gastroenterology and the principal symptom of functional bowel disorders. This symptom is often associated with gut hypersensitivity to distension. The use of animal models has recently permitted the identification of some mediators supposed to play a pivotal role in the genesis of visceral hypersensitivity. Serotonin, through different receptor subtypes, as well as kinins and calcitonin gene-related peptide, are known to be involved, but other putative transmitters arise and are new potential targets for the development of efficacious treatments. This themes article addresses both physiological and preclinical issues of interest for the selection of active new drugs in regard to the clinical pharmacology of visceral pain.


Author(s):  
Jenny Gordon

The aim of this chapter is to provide nurses with the knowledge to be able to assess, manage, and care for people with the group of conditions often described as functional bowel disorders (FBD)—see definitions below—in an evidence-based and person-centred way. The chapter will provide an overview of the causes and impact of FBDs, before exploring best practice to deliver care, as well as to prevent or to minimize further ill-health. Nursing assessments and priorities are highlighted throughout, and the nursing management of the symptoms and common health problems associated with FBDs can be found in Chapters 16, 23, 24, and 25, respectively. This chapter discusses the group of conditions often described as functional bowel disorders (FBDs). The term ‘functional gastrointestinal disorders’ is also used in the literature, but, for the purpose of this book, the term FBDs will be adopted. This refers to a group of disorders that are characterized by chronic gastrointestinal symptoms that currently have an unknown structural or biochemical cause that could explain those symptoms. Rome III is an internationally agreed set of diagnostic criteria and related information on functional gastrointestinal disorders (Longstreth et al., 2006). It includes six major domains for adults: oesophageal; gastro/duodenal; bowel; functional abdominal pain syndrome; biliary; and anorectal. This chapter will cover the FBDs that specifically relate to chronic abdominal symptoms. General abdominal symptoms include functional dyspepsia, non-cardiac chest pain, which may mimic functional abdominal symptoms, chronic abdominal pain, functional constipation, functional diarrhoea, functional bloating, and irritable bowel syndrome (IBS). The chapter will concentrate on irritable bowel syndrome. Coeliac disease and Crohn’s disease are included: to give an understanding of these disorders, and to differentiate between inflammatory and non-inflammatory conditions; to highlight the impact of the symptoms on the people who suffer from them; and to give an insight into the contribution that effective nursing makes. The amount of research and the number of publications concerning FBDs has risen considerably since the mid 1990s, and has contributed to the increasing legitimacy of these conditions as disorders in their own right and not simply by virtue of exclusion of all other possibilities.


Author(s):  
Dr. Laxminarayan Nagal ◽  
Dr. Jagdish Dabi ◽  
Dr. Harish Kumar Mourya

Background: Study aimed to determine prevalence and clinical profile of functional pain abdomen in children in the age group of 5-14 years coming to the pediatric OPD. Methods: Hospital based prospective case control study conducted on children aged 5 to 15 years in routine OPD and indoor patient fulfilling the inclusion criteria.   Results: In the present study, out of 100 cases, 68.00% children were male and 32.00% children were female. Most of children (74.00%) were 5-10 Yrs age group. According to clinical symptoms and investigations, 47(47.00%) children had symptoms suggestive of IBS, 25 (25.00%) children had Dyspepsia, 11 (11.00%) children had Functional pain abdomen, 4 (4.00%) children had FAPS, 2 (2.00%) children had Giardiasis, 1 (1.0%) children had right ovarian cyst, 3 (3.00%) children had coeliac disease, 2 (2%) children had cystitis and 5(5.00%) children had gastritis. Conclusion: Functional pain abdomen is a common complaint of childhood with associated familial, psychological, and co-morbid conditions. Epidemiologic studies of Functional pain abdomen in children may offer information on the evolution of functional bowel disorders through the lifespan. Keywords: Bowel disorder, Functional abdominal pain (FAP), Chronic abdominal pain.


1997 ◽  
Vol 25 (5) ◽  
pp. 225-246 ◽  
Author(s):  
M Delvaux ◽  
D Wingate

The actions of trimebutine [3,4,5-trimethoxybenzoic acid 2-(dimethylamino)-2-phenylbutylester] on the gastrointestinal tract are mediated via (i) an agonist effect on peripheral μ, k and δ opiate receptors and (ii) release of gastrointestinal peptides such as motilin and modulation of the release of other peptides, including vasoactive intestinal peptide, gastrin and glucagon. Trimebutine accelerates gastric emptying, induces premature phase III of the migrating motor complex in the intestine and modulates the contractile activity of the colon. Recently, trimebutine has also been shown to decrease reflexes induced by distension of the gut lumen in animals and it may therefore modulate visceral sensitivity. Clinically, trimebutine has proved to be effective in the treatment of both acute and chronic abdominal pain in patients with functional bowel disorders, especially irritable bowel syndrome, at doses ranging from 300 to 600 mg/day. It is also effective in children presenting with abdominal pain.


Sign in / Sign up

Export Citation Format

Share Document